The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
This presentation discusses evidence-based comprehensive evaluation of and treatment for urologic conditions manifested from neurologic disorders including current practice guidelines.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 10/18/22.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: Christina Hegan, MS, APRN, WHNP-BC Consultant for Urovant Sciences Spouse is a distributor for CBD rich hemp oil
There are no other Planning Committee disclosures to declare.
Speakers Conflict of Interest Disclosure: Gina Powley, MSN, ANP-BC Speakers Bureau for Astellas
There are no other speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
The SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of CE in nursing does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this education activity, the learner will be able to identify patients with neurogenic bladder and develop a comprehensive treatment plan.
This presentation compares and contrasts the current available UTI guidelines. The new UTI guidelines presented in May at the AUA, The Infectious Disease Society Asymptomatic Bacteriuria 2019 guidelines, The AUA, SUFU, CUA recurrent UTI guidelines among others are highlighted…
Advanced prostate cancer treatments continue to evolve with new treatments in the M0CRPC, such as daralutamide and apalutamide, precision treatments based on genetic testing including PARP inhibitors and PD1 immunotherapy…
Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.